Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treosulfan and Total-marrow Irradiation (TMI) Based Conditioning With Rapamycin Based Graft vs. Host Disease (GvHD) Prophylaxis for Allogenic Stem Cell Transplantation (Allo-HSCT) in Patients With High-risk Hematological Malignancies

NCT03963024 is registered in ClinicalTrials.gov with IRCCS San Raffaele as lead sponsor.

NCT NCT03963024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03963024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treosulfan and Total-marrow Irradiation (TMI) Based Conditioning With Rapamycin Based Graft vs. Host Disease (GvHD) Prophylaxis for Allogenic Stem Cell Transplantation (Allo-HSCT) in Patients With High-risk Hematological Malignancies
Lead sponsor
IRCCS San Raffaele
Phase
Phase 1
Overall status
Terminated
Start date
February 12, 2014
Completion date
January 31, 2019
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft vs host disease, irradiated bone marrow, leukemia, acute, multiple myeloma, transplant-related hematologic malignancy